---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030320"
form_type: "8-K"
ticker: "APTN"
cik: "0001938571"
company_name: "ADAPTIN BIO, INC."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:36:45.857663+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial

## Summary
- Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.
- Private placement of 1,400,342 shares with Series A (1-yr, $4.40) and Series B (5-yr, $6.60) warrants.
- $1.5M promissory notes converted at $3.30/share; total gross proceeds ~$7.7M.
- Proceeds to fund Phase 1 trial of APTN-101 for glioblastoma after FDA IND clearance.
- Post-closing: Lucius Partners and former Adaptin holders each hold ~3.25M shares.

## SEC filing metadata
- accession: 0001213900-25-030320
- form_type: 8-K
- ticker: APTN
- cik: 0001938571
- company_name: ADAPTIN BIO, INC.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/0001213900-25-030320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/ea0237436-8k_adaptin.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030320
- JSON: https://secwatch.observer/filing/0001213900-25-030320.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.